Literature DB >> 8087487

The depth-dependent radiation response of human melanoma cells exposed to 65 MeV protons.

A Courdi1, N Brassart, J Hérault, P Chauvel.   

Abstract

Radiation therapy with positively charged particles implies that the Bragg peak be spread out to deliver a homogeneous dose to the tumour. The spread-out Bragg peak (SOBP) has a higher linear energy transfer (LET) than the entrance beam. In addition, there is an LET gradient from proximal to distal SOBP. The aim of this study is to find out whether these small LET variations lead to differences in radiation response. Human melanoma cells (CAL4) were exposed to 65 MeV proton beams produced by the cyclotron Medicyc at five different positions: 2 mm depth corresponding to the entrance, 15, 20, 25 and 26.8 mm depth corresponding to four different positions in the half-modulated SOBP. Survival curves were generated using the in vitro colony method and fitted with the linear-quadratic model. Survival differences were observed at high doses; they were statistically significant at a dose of 8 Gy. With respect to the entrance position (2 mm), the relative biological effectiveness (RBE) at 1% survival was 1.09, 1.12, 1.19 and 1.27 at 15, 20, 25 and 26.8 mm in the SOBP, respectively. Whereas RBE values in the SOBP greater than 1.0 relative to the entrance beam represent a small biological advantage to be added to the well-known physical advantage of high energy proton beams; the RBE gradient along the SOBP would imply that the distal end of the tumour would receive a higher biologically equivalent dose than the proximal end, despite a homogeneous physical dose, especially at the high doses per fraction given in ocular melanomas. Although the increase in effectiveness with depth is mild, it should be kept in mind during eye treatment planning, in case a critical target is present at the extreme end of the SOBP.

Entities:  

Mesh:

Year:  1994        PMID: 8087487     DOI: 10.1259/0007-1285-67-800-800

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  8 in total

1.  Comparison of radiobiological effective depths in 65-MeV modulated proton beams.

Authors:  J T Tang; T Inoue; T Inoue; H Yamazaki; S Fukushima; N Fournier-Bidoz; M Koizumi; S Ozeki; K Hatanaka
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Relative biological effectiveness of the 60-MeV therapeutic proton beam at the Institute of Nuclear Physics (IFJ PAN) in Kraków, Poland.

Authors:  Dorota Słonina; Beata Biesaga; Jan Swakoń; Damian Kabat; Leszek Grzanka; Marta Ptaszkiewicz; Urszula Sowa
Journal:  Radiat Environ Biophys       Date:  2014-07-19       Impact factor: 1.925

3.  Proton Relative Biological Effectiveness - Uncertainties and Opportunities.

Authors:  Harald Paganetti
Journal:  Int J Part Ther       Date:  2018-09-21

4.  Investigating the Implications of a Variable RBE on Proton Dose Fractionation Across a Clinical Pencil Beam Scanned Spread-Out Bragg Peak.

Authors:  Thomas I Marshall; Pankaj Chaudhary; Anna Michaelidesová; Jana Vachelová; Marie Davídková; Vladimir Vondráček; Giuseppe Schettino; Kevin M Prise
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-13       Impact factor: 7.038

Review 5.  Clinical Progress in Proton Radiotherapy: Biological Unknowns.

Authors:  Laura Vanderwaeren; Rüveyda Dok; Kevin Verstrepen; Sandra Nuyts
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

6.  A High-Precision Method for In Vitro Proton Irradiation.

Authors:  Michelle E Howard; Janet M Denbeigh; Emily K Debrot; Nicholas B Remmes; Michael G Herman; Chris J Beltran
Journal:  Int J Part Ther       Date:  2020-10-01

7.  Comparison of human chordoma cell-kill for 290 MeV/n carbon ions versus 70 MeV protons in vitro.

Authors:  Hiroshi Fujisawa; Paula C Genik; Hisashi Kitamura; Akira Fujimori; Mitsuru Uesaka; Takamitsu A Kato
Journal:  Radiat Oncol       Date:  2013-04-15       Impact factor: 3.481

8.  Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.

Authors:  Aleksandra M Ristić-Fira; Lela B Korićanac; Jelena J Zakula; Lucia M Valastro; Gioacchin Iannolo; Giuseppe Privitera; Giacomo Cuttone; Ivan M Petrović
Journal:  J Exp Clin Cancer Res       Date:  2009-04-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.